Clinical Study on the Use of Huaier Granules for the Treatment of Proteinuria Related to Bevacizumab and Anlotinib in Lung Cancer Patients

Korábbi kezelés

• Inability to take oral medication;
• Required or ongoing use of drugs known to potentially affect proteinuria, including but not limited to ACE inhibitors, glucocorticoids (>3 weeks), and Chinese patent medicines (as per respective drug prescribing information);
• Currently participating in other clinical trials investigating drugs for treating proteinuria;

Más betegség

• Known allergy, contraindication, or caution to any component of Huaier Granules;
• Proteinuria caused by underlying diseases, including but not limited to nephropathy, hypertension, urinary tract infection, systemic lupus erythematosus, multiple myeloma, etc.;

Egyéb

• Women who are pregnant, breastfeeding, or planning pregnancy;
• Refusal to cooperate with follow-up;
• Any other reasons deemed by the investigator as unsuitable for participation in this study.

• Age ≥18 years;
• Histopathologically confirmed diagnosis of lung cancer;
• Receiving Bevacizumab or Anlotinib treatment;
• Positive urine protein detection, with 0.15g < 24-hour urinary protein quantification < 3.5g;
• No treatment with Huaier Granules within one month prior to enrollment;
• Expected survival time not less than 6 months;
• Voluntary participation in this study and provision of signed informed consent.